Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.
Hammami I. et al, (2025), Heart
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.
Petrucci G. et al, (2024), Eur Heart J, 45, 1355 - 1367
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study
MIHAYLOVA B. et al, (2024), The Lancet Regional Health - Europe
Thromboxane biosynthesis and risk of future events in diabetes mellitus: A sub-study of the ASCEND trial.
PARISH S. et al, (2023), European Heart Journal
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model
Wu R. et al, (2023), British Journal of General Practice
Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Baigent C. and Sádaba R., (2023), Eur Heart J
Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Baigent C. and Sádaba R., (2023), Eur J Cardiothorac Surg, 64
Empagliflozin in Patients with Chronic Kidney Disease. Reply.
Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
HERRINGTON W. et al, (2023), Kidney International Reports
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Chapman D. et al, (2023), Kidney Int
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert M. et al, (2023), European Respiratory Journal, 61
Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK
Zhou J. et al, (2022), PharmacoEconomics
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology